Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5988
- Registration Number
- NCT03057951
- Locations
- 🇺🇸
Atlanta Heart Specialists, LLC, Tucker, Georgia, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸Covigilant Research, LLC, Riverside, California, United States
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3730
- Registration Number
- NCT03057977
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Integrated Heart Care, Boca Raton, Florida, United States
Characteristics of Empagliflozin Initiators
- Conditions
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31908
- Registration Number
- NCT03050619
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Jichi Medical University
- Target Recruit Count
- 174
- Registration Number
- NCT03050229
- Locations
- 🇯🇵
Kotake Hospital, Fukuoka, Japan
🇯🇵Onga Hospital, Fukuoka, Japan
🇯🇵Ishiguro Clinic, Gifu, Japan
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- Conditions
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 21
- Registration Number
- NCT03027960
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Empagliflozin vs Metformin in PCOS
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Hull University Teaching Hospitals NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT03008551
- Locations
- 🇬🇧
Michael White Centre for Diabetes and Endocrinology, Hull, East Yorkshire, United Kingdom
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 97
- Registration Number
- NCT02998970
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 6
- Registration Number
- NCT02985242
- Locations
- 🇩🇪
Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 61
- Registration Number
- NCT02964572
- Locations
- 🇰🇷
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center, Seoul, Korea, Republic of
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 25
- Registration Number
- NCT02964715
- Locations
- 🇲🇾
University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.